<?xml version="1.0" encoding="UTF-8"?>
<list>
  <sentences>
    <s path="[OANC]/data/written_2/technical/biomed/1471-2180-2-20.anc" start="19532" end="19539" sStart="19477" offset="55" sid="null" wn="3" wnkey="suggest%2:32:02::" text="However, this observation does not necessarily suggest direct activation because the effect cellular activation may have on EBV latency is not known." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2180-2-20.anc" start="19532" end="19539" sStart="null" offset="55" sid="r8.suggest.v.0665" wn="3" wnkey="suggest%2:32:02::" text="However, this observation does not necessarily suggest direct activation because the effect cellular activation may have on EBV latency is not known." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2180-2-20.anc" start="19532" end="19539" sStart="null" offset="55" sid="null" wn="3" wnkey="suggest%2:32:02::" text="However, this observation does not necessarily suggest direct activation because the effect cellular activation may have on EBV latency is not known." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2180-2-20.anc" start="19532" end="19539" sStart="null" offset="55" sid="null" wn="3" wnkey="suggest%2:32:02::" text="However, this observation does not necessarily suggest direct activation because the effect cellular activation may have on EBV latency is not known." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2180-2-20.anc" start="19532" end="19539" sStart="null" offset="55" sid="null" wn="3" wnkey="suggest%2:32:02::" text="However, this observation does not necessarily suggest direct activation because the effect cellular activation may have on EBV latency is not known." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2180-2-20.anc" start="19297" end="19306" sStart="null" offset="109" sid="r8.suggest.v.0319" wn="3" wnkey="suggest%2:32:02::" text="observed that HHV-6 (same subfamily as CMV) could cause the reactivation of EBV [ 33 ] . The authors suggested that HHV-6 was having a direct effect on EBV reactivation because they were able to observe the presence of both viral antigens in the same cell." />
    <s path="file:/c:/OANC/data/written_2/technical/biomed/1471-2180-2-20.anc" start="5666" end="5671" sStart="null" offset="0" sid="null" wn="4" wnkey="show%2:39:00::" text="The CMV standards (5 ? 10 5, 5 ? 10 3, and 5 ? 10 1) for the BJAB-B1 cells are &lt;b&gt;shown&lt;/b&gt; (Figure 1C) and the standards for the P3HR-1 cells were not &lt;b&gt;shown&lt;/b&gt;." />
    <s path="file:/c:/OANC/data/written_2/technical/biomed/1471-2180-2-20.anc" start="5414" end="5419" sStart="null" offset="0" sid="null" wn="3" wnkey="show%2:32:00::" text="The CMV MIE transcript was present in the BJAB-B1 and P3HR-1 cells superinfected with CMV at all &lt;b&gt;time&lt;/b&gt; points as &lt;b&gt;shown&lt;/b&gt; by the real-time PCR data (Figures 1Aand 2A, respectively)." />
    <s path="file:/c:/OANC/data/written_2/technical/biomed/1471-2180-2-20.anc" start="10847" end="10852" sStart="null" offset="0" sid="null" wn="2" wnkey="show%2:31:00::" text="This project has &lt;b&gt;shown&lt;/b&gt; that the BJAB-B1 and P3HR-1 cells were susceptible to a CMV superinfection by detecting viral transcript and protein." />
    <s path="file:/c:/OANC/data/written_2/technical/biomed/1471-2180-2-20.anc" start="3086" end="3092" sStart="null" offset="0" sid="null" wn="2" wnkey="show%2:31:00::" text="Such studies would be interesting since CMV infection has been suggested as a risk factor for the development of PTLD [ 22 24 ] . Investigators have &lt;b&gt;showed&lt;/b&gt; that a large percentage of transplant patients who had developed PTLD also had CMV disease [ 22 30 ] . In addition to CMV being implicated as a factor for the development of PTLD, serological studies have &lt;b&gt;shown&lt;/b&gt; that patients with an active CMV infection experienced a serological profile of EBV reactivation [ 22 31 32 ] . Cross reactivities between the two viruses were ruled out as a cause for the observed immunoreactivations." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1471-2180-2-20.anc" start="33591" end="33595" sStart="null" offset="0" sid="null" wn="4" wnkey="read%2:31:06::" text="Samples and standards were placed in a microtiter plate and &lt;b&gt;read&lt;/b&gt; on the CytoFluor reader from Applied Biosystems (Foster City, CA) (excitation 485 nm/20 nm and emission 530 nm/25 nm)." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1471-2180-2-20.anc" start="31169" end="31173" sStart="null" offset="0" sid="null" wn="1" wnkey="read%2:31:00::" text="Cells were washed in PBS and then 750 ?l of paraformaldehyde was &lt;b&gt;added&lt;/b&gt; and &lt;b&gt;read&lt;/b&gt; on the FACScalibur flow cytometer (Becton Dickinson, Los Angeles, CA)." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2180-2-20.anc" start="13793" end="13803" sStart="null" offset="74" sid="r10.particular.j.0149" wn="2147483647" wnkey="null" text="Numerous studies have been able to show that PBMCs and B-cells in particular can have expression of viral transcript and/or antigen [ 35 36 37 38 39 40 41 ] however, other studies have been contradictory [ 40 42 ] and therefore no consensus among the observations noted." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1471-2180-2-20.anc" start="15348" end="15352" sStart="null" offset="0" sid="null" wn="1" wnkey="lose%2:40:02::" text="The strain used in this study, AD169, and the Towne strains were both used to develop vaccines [ 49 ] . Differences in infectivity have been observed between 2 of the same strains of CMV and this may be attributed to the deletion or mutation of certain tropism genes upon extensive serial propagation [ 50 51 ] . Clinical isolates (wild-type CMV) can carry more than 220 genes, and some of these genes can be &lt;b&gt;lost&lt;/b&gt; by deletion and/or rearrangement during laboratory passage [ 50 ] . The AD169 strain used in this study has been passaged many times and because of these variations observed among the CMV strains, this may partly account for the low infectivity observed in the BJAB-B1 and P3HR-1 cells." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2180-2-20.anc" start="7403" end="7407" sStart="null" offset="180" sid="r9.late.j.0995" wn="6" wnkey="late%3:00:02::" text="The p52 gene expresses a DNA binding protein that is present in the nuclei of infected cells beginning in the early phase of infection through to the late phase." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2180-2-20.anc" start="16862" end="16866" sStart="null" offset="100" sid="r9.late.j.0292" wn="6" wnkey="late%3:00:02::" text="During a replicative infection, expression of this protein continues through to the late phase of infection [ 56 ] . One function of the p52 protein is to aid in replication by binding to the viral DNA polymerase." />
    <s path="file:/c:/OANC/data/written_2/technical/biomed/1471-2180-2-20.anc" start="20766" end="20771" sStart="null" offset="0" sid="null" wn="2147483647" wnkey="null" text="CMV has been &lt;b&gt;shown&lt;/b&gt; to cause calcium flow and protein kinase C (PKC) activation that could then be involved in the early activation of transcription factors [ 71 ] . Cellular levels of secondary messengers inositol 1,4,5-triphosphate and 1,2-diacylglycerol [ 71 72 73 ] , as well as the MAP kinases (ERK1 and ERK2) [ 74 75 ] are also &lt;b&gt;known&lt;/b&gt; to be upregulated, which may have an effect on EBV reactivation." />
    <s path="file:/c:/OANC/data/written_2/technical/biomed/1471-2180-2-20.anc" start="20766" end="20771" sStart="null" offset="0" sid="null" wn="1" wnkey="know%2:31:01::" text="CMV has been &lt;b&gt;shown&lt;/b&gt; to cause calcium flow and protein kinase C (PKC) activation that could then be involved in the early activation of transcription factors [ 71 ] . Cellular levels of secondary messengers inositol 1,4,5-triphosphate and 1,2-diacylglycerol [ 71 72 73 ] , as well as the MAP kinases (ERK1 and ERK2) [ 74 75 ] are also &lt;b&gt;known&lt;/b&gt; to be upregulated, which may have an effect on EBV reactivation." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2180-2-20.anc" start="31445" end="31453" sStart="null" offset="88" sid="r10.control.n.0595" wn="4" wnkey="control%1:09:02::" text="CMV infected and uninfected MRC-5 fibroblasts were used as positive controls for viable CMV and antibody staining." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1471-2180-2-20.anc" start="31059" end="31064" sStart="null" offset="0" sid="null" wn="1" wnkey="add%2:30:00::" text="During the permeabilization step, FITC-labelled antibody (p52) was &lt;b&gt;added&lt;/b&gt; at a 1:5 dilution." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1471-2180-2-20.anc" start="31159" end="31164" sStart="null" offset="0" sid="null" wn="1" wnkey="add%2:30:00::" text="Cells were washed in PBS and then 750 ?l of paraformaldehyde was &lt;b&gt;added&lt;/b&gt; and &lt;b&gt;read&lt;/b&gt; on the FACScalibur flow cytometer (Becton Dickinson, Los Angeles, CA)." />
  </sentences>
</list>